Strategic Investments A/S : Q3 investment profit 19.0 million Danish crowns ($2.8 million) versus loss 3.5 million crowns year ago . Q3 pretax profit 18.2 million crowns versus loss 4.1 million crowns year ago .2016 outlook unchanged.
Lindblad Expeditions Holdings Inc : Reports 2016 third quarter financial results . Q3 earnings per share $0.16 . Q3 revenue $70.8 million .As of October 31, 2016, Lindblad segment had 95% of full year 2016 projected guest ticket revenues on books.
Oresund AB :Net asset value on Oct. 31 up 25.7 percent at 125 Swedish crowns per share.
Porto Group Holding Sae : Nine-month standalone net loss EGP 9.6 million Source: (http://bit.ly/2eWvQKU) Further company coverage: [PORT.CA] ((Bangalore.email@example.com;)).
Porto Group Holding : Nine-month consol net profit EGP 69.3 million . Nine-month consol revenue egp 664.8 million Source: (http://bit.ly/2fck66b) Further company coverage: [PORT.CA] ((Bangalore.firstname.lastname@example.org;)).
Transnational Corporation Of Nigeria Plc : 9-month loss before tax 12.78 billion naira versus profit of 7.19 billion naira last year .9-month revenue 41.92 billion naira versus 30.43 billion naira last year.
Small Cap Danmark A/S :Q3 pre-tax profit 20.8 million Danish crowns ($3.04 million) versus 8.1 million crowns year ago.
Lifco AB (Publ) : Q3 net sales increased by 11.4 percent to SEK 2,128 (1,910) million . Says organically net sales decreased by 0.2 per cent . Q3 EBITA, before restructuring, integration and acquisition costs, increased by 12.6 percent to SEK 316 (280) million . Says, even after this year's nine consolidated businesses, we still have significant financial scope for further acquisitions Further company coverage: [LIFCOb.ST] (Stockholm Newsroom) ((email@example.com; +46 (0) 8-700 1010;)).
Actinium Pharmaceuticals Inc : Actinium Pharmaceuticals Inc - company has initiated european medicines agency scientific advice process for Iomab-B .Actinium Pharmaceuticals-scientific advice process allows dialogue with EMA regulators to determine appropriate development program for Iomab-B in Europe.
M&C SpA : Finalizes contracts with Dea Capital SpA for sale of all of its shares and rights in fund Idea EESS (IDeA Efficienza Energetica e Sviluppo Sostenibile) for a total of 5.3 million euros ($5.94 million) . Idea EESS is a closed-end investment fund reserved to qualified investors managed by IDeA Capital Funds SGR, a wholly-owned unit of DeA Capital .The units involved in the transaction represent 15.1 percent of the total size of the fund, of which DeA Capital already owns 15.3 percent.